Histafen (Chlorpheniramine maleate): Discontinuation
Douglas Pharmaceuticals are discontinuing Histafen.
Reason for this discontinuation
The formulation for Histafen has remained unchanged for 50 years. Douglas only supplies Histafen to New Zealand. Due to the relatively low use and high cost of manufacturing compliance, Douglas have advised it is no longer sustainable to continue manufacturing and supply.
When will this happen
Current stocks of Histafen were expected to run out in July 2023.
We will delist this product from the Schedule in early 2024.
There are ample modern antihistamines on the market.
Who to contact
If you use Histafen, talk to the person who prescribed it to you about the best alternative antihistamine for you. Pharmac cannot comment on any individual's clinical circumstances, so we cannot advise you.
If you have questions relating to funding for Histafen, email firstname.lastname@example.org